


PRODUCT INFORMATION



LNP GalNAc Ligand 1 (trifluoroacetate salt)

Item No. 38952

CAS Registry No.: 1159408-65-7
Formal Name: 6-amino-11,17-dioxo-6-[[[3-oxo-3-[[[3-[[[1-oxo-5-[[[3,4,6-tri-O-acetyl-2-(acetyl-amino)-2-deoxy-β-D-galactopyranosyl]oxy]pentyl]amino]propyl]amino]propoxy]methyl]-N-[3-[[[1-oxo-5-[[[3,4,6-tri-O-acetyl-2-(acetyl-amino)-2-deoxy-β-D-galactopyranosyl]oxy]pentyl]amino]propyl]-21-[[[3,4,6-tri-O-acetyl-2-(acetyl-amino)-2-deoxy-β-D-galactopyranosyl]oxy]-4,8-dioxo-12,16-diazaheneicosanamide, mono(2,2,2-trifluoroacetate)



Synonyms: LNP N-Acetylgalactosamine Ligand 1, Lipid Nanoparticle N-Acetylgalactosamine Ligand 1, Lipid Nanoparticle GalNAc Ligand 1

MF: C₇₉H₁₂₈N₁₀O₃₆ • CF₃COOH

FW: 1,908.0

Purity: ≥95%

Supplied as: A solid

Storage: -20°C

Stability: ≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

LNP GalNAc ligand 1 (trifluoroacetate salt) is supplied as a solid. A stock solution may be made by dissolving the LNP GalNAc ligand 1 (trifluoroacetate salt) in the solvent of choice, which should be purged with an inert gas. LNP GalNAc ligand 1 (trifluoroacetate salt) is sparingly soluble (1-10 mg/ml) in ethanol and DMSO.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of LNP GalNAc ligand 1 (trifluoroacetate salt) can be prepared by directly dissolving the solid in aqueous buffers. LNP GalNAc ligand 1 (trifluoroacetate salt) is sparingly soluble (1-10 mg/ml) in PBS (pH 7.2). We do not recommend storing the aqueous solution for more than one day.

Description

LNP GalNAc ligand 1 is a multivalent N-acetylgalactosamine (GalNAc) asialoglycoprotein receptor (ASGPR) targeting ligand.¹ It has been used in the formation of lipid nanoparticles (LNPs) for the hepatic delivery of CRISPR base editors in mice.

Reference

1. Kasiewicz, L.N., Biswas, S., Beach, A., *et al.* GalNAc-Lipid nanoparticles enable non-LDLR dependent hepatic delivery of a CRISPR base editing therapy. *Nat. Commun.* **14**(1), 2776 (2023).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/08/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM